No increas

No increased risk of hypertension, pre-eclampsia after SARS-CoV-2 infection during pregnancy

Findings from a study published in BMJ Medicine showed no increased risk of hypertension during pregnancy or pre-eclampsia after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during pregnancy.  The study found that the results were similar for SARS-CoV-2 infection in any trimester, during times corresponding to the different dominant variants of the SARS-CoV-2, and when adjusting for vaccination status. “Severe COVID-19 has been shown to have multiorgan effects and symptomatology, similar to those seen in individuals with hypertension during pregnancy,” wrot...

SGLT2i for evidence based cardiorenal protection in diabetic and non-diabetic chronic kidney di...

Chronic kidney disease (CKD) is a major public health issue affecting an estimated 850 million people globally. The leading causes of CKD is diabetes and hypertension, which together account for more than 50% of patients with end-stage kidney disease

Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy

CONTEXT Differences in recovery, oncological, and quality of life (QoL) outcomes between open radical cystectomy (ORC) and robot-assisted radical cystectomy (RARC) for patients with bladder cancer are unclear. OBJECTIVE This review aims to c...


Spotify episodes

Apple podcasts

Google podcasts

Search:
Date
Filters:
HER2 treat
12:07

HER2 treatment landscape 2023

Presenter: Javier Cortes
Oncology : Breast Cancer
ESMO Breast Cancer 2023
Do overwei
6:30

Do overweight and obesity confer an additional risk of CAD in patients with FH?

Presenter: Amany Elshorbagy
Cardiology : Atherosclerosis
EAS 2023
Objective
6:01

Objective assessement of skin disease severity with the help of AI

Presenter: Maksym Breslavets
Dermatology
EADV Symposium 2023
What's new
8:09

What's new in treatment of breast cancer? - Highlights of ESMO BC 2023

Presenter: Matteo Lambertini
Oncology : Breast Cancer
ESMO Breast Cancer 2023
Hot topics
15:11

Hot topics in melanoma management

Presenter: Paolo A. Ascierto
Oncology
EADO 2023
Functional
10:33

Functional Precision Medicine in Oncology

Presenter: Anthony Letai
Oncology
AACR 2023
The first
14:14

The first mRNA cancer vaccine with pembrolizumab minimizes recurrence rate in melanoma tells Jeffrey Weber clinical investigator

Presenter: Jeffrey Weber
Oncology
AACR 2023
Current is
13:39

Current issues in the treatment of schizophrenia

Presenter: Istvan Bitter
Psychiatry
EPA 2023
Highlights
10:47

Highlights of EPA 2023

Presenter: Peter Falkai
Psychiatry
EPA 2023
The Risk o
5:25

The Risk of Early Recurrent MI: What is the Role of Cholesterol Efflux and ApoA-I?

Presenter: Eliot A. Brinton
Cardiology
ACC 2023
Bempedoic
5:48

Bempedoic Acid Improves Cardiovascular Outcomes In Statin Intolerant Patients At High Cardiovascular Risk

Presenter: Eliot A. Brinton
Cardiology
ACC 2023
How to inc
6:19

How to increase prescription of evidence-based therapies in adults with T2D and ASCVD? - The COORDINATE-Diabetes Study

Presenter: Neha Pagidipati
Cardiology
ACC 2023
The FREEDO
6:42

The FREEDOM COVID Anticoagulation Strategy Randomized Trial

Presenter: Gregg Stone
Cardiology
ACC 2023
Minimally
7:09

Minimally Invasive Versus Conventional Sternotomy For Mitral Valve Repair Surgery - UK Mini Mitral Trial

Presenter: Enoch Akowuah
Cardiology
ACC 2023
Can Patien
3:56

Can Patients with Hypertrophic Cardiomyopathy do Vigorous Exercise? - A Multinational Lifestyle And Exercise Study

Presenter: Rachel Lampert
Cardiology
ACC 2023
Efficacy a
3:31

Efficacy and Safety of Oral PCSK9 Inhibitor, MK-0616 in the Treatment of Hypercholesterolemia

Presenter: Eliot A. Brinton
Cardiology
ACC 2023
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
Do overwei
0:54

Do overweight and obesity confer an additional risk of CAD in patients with FH?

Presenter: Amany Elshorbagy
Cardiology
Interrupti
1:17

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

Presenter: Matteo Lambertini
Oncology
The Omega-
1:17

The Omega-3 Mystery: New Evidence Supports the Therapeutic Value of EPA

Presenter: Eliot A. Brinton
Cardiology
The issue
1:15

The issue of adjuvant vs neoadjuvant treatment

Presenter: Paolo A. Ascierto
Oncology
The treatm
1:19

The treatment sequence in metastatic melanoma

Presenter: Paolo A. Ascierto
Oncology
LMWH use i
1:12

LMWH use in pregnancy: The ALPINE trial

Presenter: Saskia Middeldorp
Hematology
Functional
1:19

Functional Precision Medicine in Oncology

Presenter: Anthony Letai
Oncology
The first
1:10

The first mRNA cancer vaccine with pembrolizumab minimizes recurrence rate in melanoma tells Jeffrey Weber clinical investigator

Presenter: Jeffrey Weber
Oncology
Elevated L
1:18

Elevated Lipoprotein(a) as a Risk Enhancing Factor for Atherosclerotic Cardiovascular Disease

Presenter: Nathan D. Wong
Cardiology
Long-term
8:46

Long-term efficacy and safety of ixekizumab

Presenter: Andrew Blauvelt
Dermatology
Paradigm s
12:05

Paradigm shift in the early NSCLC? The role of ICIs in the adjuvant treatment

Presenter: Federico Cappuzzo
Oncology
How will t
9:43

How will the current therapeutic options change the treatment of RCC in the daily practice?

Presenter: Camillo Porta
Oncology
The role o
5:58

The role of immune checkpoint inhibitors and VEGF TKIs in the adjuvant treatment of renal cell carcinoma

Presenter: David F. McDermott
Oncology
Treatment
11:50

Treatment intensification in the treatment of prostate cancer

Presenter: Oliver Sartor
Oncology
Pembrolizu
16:35

Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma

Presenter: Stefan N. Symeonides
Oncology
State of t
6:13

State of the art treatment of bladder cancer

Presenter: Matthew R. Zibelman
Oncology